Acutus Medical, Inc.
AFIBHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $20.2M | $7.2M | $3.0M | $17.3M | $8.5M | $2.8M |
| Operating income | −$57,000 | −$11.7M | $41.0M | −$112.1M | −$91.3M | −$72.6M |
| Net income | −$9.5M | −$81.7M | −$39.6M | −$117.7M | −$102.0M | −$97.0M |
| Total assets | $28.6M | $54.0M | $133.4M | $169.8M | $192.5M | $105.5M |
| Total liabilities | $40.2M | $54.8M | $58.4M | $64.1M | $66.0M | $77.9M |
| Equity | −$11.6M | −$879,000 | $75.0M | $105.7M | $126.6M | −$225.8M |
| EPS (diluted) | $-0.32 | $-2.81 | $-1.40 | $-4.11 | $-8.94 | — |
| Shares out. | 29.7M | 28.9M | 28.3M | 28.1M | 28.0M | 695,902 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −0.3%
- Net margin
- −47.4%
- Return on equity
- 82.4%
- Return on assets
- −33.3%
- Return on capital (ROCE)
- −0.4%
- Liabilities / assets
- 140.5%
- Debt / equity
- —
- Book value / share
- $-0.39
- Revenue growth (YoY)
- 181.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -66.67distress
- Accruals / assets
- 77.2%high accruals
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Advent Life Sciences LlpPassive (13G)Feb 17, 2026
- Flynn James EActivist (13D)Jan 28, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 859 | 1.0 | 0.0% |
| Apr 30, 2026 | 859 | 1.0 | 0.0% |
| Apr 15, 2026 | 859 | 1.0 | 0.0% |
| Mar 31, 2026 | 859 | 1.0 | 0.0% |
| Mar 13, 2026 | 859 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMar 24, 2025
- Entered a material agreement · Modified shareholder rights · Other material eventJan 21, 2025
- Costs from exit or disposal · Director / officer change · Regulation FD disclosureDec 4, 2024
- Entered a material agreementNov 15, 2024
- Results of operationsNov 14, 2024
- Entered a material agreement · Terminated a material agreementOct 17, 2024
- Results of operationsAug 8, 2024
- Shareholder voteJun 14, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AFeb 17, 2026
- 10-KMar 24, 2025
- 8-KMar 24, 2025
- 4Jan 28, 2025
- SCHEDULE 13D/AJan 28, 2025
- 15-15DFORM 15-15DJan 24, 2025
- EFFECTJan 23, 2025
- EFFECTJan 23, 2025
- SCHEDULE 13D/AJan 23, 2025
- S-8 POSFORM S-8 POSJan 21, 2025
- S-8 POSFORM S-8 POSJan 21, 2025
- S-8 POSFORM S-8 POSJan 21, 2025
- S-8 POSFORM S-8 POSJan 21, 2025
- S-8 POSFORM S-8 POSJan 21, 2025
- POS AMFORM POS AMJan 21, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.